Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Employees

711

Sector

Biotechnology & Medical Research

Calendar

19/03 - Annual General Meeting

More about the company

Quotes

Date	Price	Change	Volume
13/26/13	63.82 $	+2.31%	19,90,788
12/26/12	62.38 $	+1.35%	24,13,320
11/26/11	61.55 $	-2.18%	41,04,484
10/26/10	62.92 $	+0.45%	22,94,779
09/26/09	62.64 $	-2.91%	58,37,949

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

63.82USD

Average target price

81.36USD

Spread / Average Target

+27.49%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 02:30:00 14/02/2026 am IST			5-day change	1st Jan Change
63.82 ^USD	+2.31%		-1.08%	-3.87%

09/02	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400 Health Care	CI
09/02	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400	CI

Capitalization	893.69Cr 753.02Cr 686.82Cr 655.71Cr 1.22TCr 81TCr 1.26TCr 7.99TCr 3.17TCr 39TCr 3.35TCr 3.28TCr 1,36600Cr	P/E ratio 2026 *	-18.5x	P/E ratio 2027 *	-15.2x
Enterprise value	803.72Cr 677.21Cr 617.68Cr 589.7Cr 1.09TCr 73TCr 1.14TCr 7.18TCr 2.85TCr 35TCr 3.01TCr 2.95TCr 1,22900Cr	EV / Sales 2026 *	18x	EV / Sales 2027 *	24.5x
Free-Float	94.28%	Yield 2026 *	-	Yield 2027 *	-

09/02	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400 Health Care	CI
09/02	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400	CI
09/02	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from S&P 600 Health Care	CI
09/02	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from S&P 600	CI
06/02	Arrowhead Pharmaceuticals, Inc., Q1 2026 Earnings Call, Feb 05, 2026
06/02	Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q1 Revenue $264.0M, vs. FactSet Est of $213.9M	MT
27/01	Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	MT
27/01	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia	CI
13/01	Aligos Therapeutics, Inc. Appoints James Hassard as Executive Vice President and Chief Commercial Officer, Effective January 13, 2026	CI
13/01	Arrowhead Pharmaceuticals issues $700 million of 0.00% convertible notes due 2032 - SEC filing	RE
12/01	Arrowhead Pharmaceuticals, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 07:30 AM
08/01	Arrowhead Pharmaceuticals offers 3,100,776 shares at $64.50 per share	RE
07/01	Sarepta Therapeutics, Inc. Announces Submission of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease	CI

22/01	B. Riley Raises Price Target on Arrowhead Pharmaceuticals to $101 From $61, Keeps Buy Rating	MT
07/01	Chardan Adjusts Price Target on Arrowhead Pharmaceuticals to $80 From $60, Maintains Buy Rating	MT
11/12	RBC Raises Price Target on Arrowhead Pharmaceuticals to $80 From $52, Keeps Outperform, Speculative Risk	MT
19/11	RBC Raises Price Target on Arrowhead Pharmaceuticals to $52 From $45, Keeps Outperform, Speculative Risk	MT
12/11	Arrowhead Has Large Market Opportunity With Severe Hypertriglyceridemia Treatment, Morgan Stanley Says	MT

Arrowhead Pharmaceuticals, Inc. Share Price

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Valuation: Arrowhead Pharmaceuticals, Inc.

Chart: Arrowhead Pharmaceuticals, Inc.

Latest news: Arrowhead Pharmaceuticals, Inc.

Last Transcript: Arrowhead Pharmaceuticals, Inc.

Analysts' recommendations: Arrowhead Pharmaceuticals, Inc.

Press Releases: Arrowhead Pharmaceuticals, Inc.

News in other languages: Arrowhead Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Arrowhead Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

06/02	Arrowhead Pharmaceuticals : ARWR FQ1 2026 Script Final	PU
06/02	Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results	BU
27/01	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia	BU
21/01	Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results	BU
08/01	Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants	BU

05/01	Arrowhead Pharmaceuticals annonce l’approbation de REDEMPLOMC (plozasiran) par Santé Canada pour réduire les triglycérides chez les adultes atteints du syndrome de chylomicronémie familiale (SCF)
02/25/02	Novartis si assicura diritti di una terapia contro Parkinson
02/25/02	Novartis s'assure les droits d'une thérapie contre Parkinson
02/25/02	Novartis sichert sich Exklusivlizenz für Parkinson-Therapie von Arrowhead
02/25/02	Novartis erhält Lizenzrechte für Parkinson-Behandlung von Arrowhead

1 day	+2.31%
1 week	-1.08%
Current month	-7.95%
1 month	-3.17%
3 months	+54.68%
6 months	+239.83%
Current year	-3.87%

1 week	60.34	65.09
1 month	60.34	76.11
Current year	60.34	76.76
1 year	9.57	76.76
3 years	9.57	76.76
5 years	9.57	93.66
10 years	1.2	93.66

Manager	Title	Age	Since
Christopher Anzalone CEO	Chief Executive Officer	56	01/12/2007
Daniel Apel DFI	Director of Finance/CFO	-	13/05/2025
Peter Carignan CTO	Chief Tech/Sci/R&D Officer	-	01/08/2022

Director	Title	Age	Since
Christopher Anzalone CHM	Chairman	56	-
Mauro Ferrari BRD	Director/Board Member	66	19/08/2010
Michael Perry BRD	Director/Board Member	66	19/12/2011

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ARROWHEAD PHARMACEUTICALS, INC.	+2.31%	-1.08%	+219.90%	+89.55%	893.69Cr
ARGENX SE	+0.83%	+1.90%	+14.14%	+103.04%	5.15TCr
WUXI APPTEC CO., LTD.	-2.85%	+4.17%	+79.23%	+14.12%	4.43TCr
INSMED INCORPORATED	+1.77%	-0.74%	+87.56%	+643.75%	3.17TCr
BIONTECH SE	+0.10%	-0.70%	-11.65%	-26.44%	2.66TCr
WUXI BIOLOGICS (CAYMAN) INC.	-3.24%	+6.16%	+91.85%	-38.03%	2.12TCr
GENMAB A/S	+1.25%	-2.73%	+27.82%	-30.06%	1.86TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.13%	-1.09%	+135.43%	-	1.25TCr
AKESO, INC.	+1.54%	+4.36%	+87.87%	+135.83%	1.24TCr
SUMMIT THERAPEUTICS INC.	+2.26%	-0.20%	-30.00%	+619.23%	1.15TCr
Average	+0.28%	+0.91%	+70.21%	+167.89%	2.39TCr
Weighted average by Cap.	-0.08%	+1.29%	+56.72%	+149.56%

	2026 *	2027 *
Net sales	45Cr 38Cr 34Cr 33Cr 61Cr 4.05TCr 63Cr 400.05Cr 158.81Cr 1.96TCr 167.83Cr 164.38Cr 6.84TCr	32Cr 27Cr 24Cr 23Cr 43Cr 2.86TCr 45Cr 282.69Cr 112.22Cr 1.38TCr 118.6Cr 116.16Cr 4.83TCr
Net income	-49Cr -42Cr -38Cr -36Cr -67Cr -4.47TCr -70Cr -441.52Cr -175.28Cr -2.16TCr -185.23Cr -181.43Cr -7.55TCr	-61Cr -51Cr -47Cr -45Cr -83Cr -5.52TCr -86Cr -544.61Cr -216.2Cr -2.66TCr -228.48Cr -223.79Cr -9.31TCr
Net Debt	-90Cr -76Cr -69Cr -66Cr -122.54Cr -8.15TCr -127.32Cr -804.23Cr -319.27Cr -3.94TCr -337.4Cr -330.47Cr -14TCr	-118.17Cr -100Cr -91Cr -87Cr -160.94Cr -11TCr -167.22Cr -1.06TCr -419.33Cr -5.17TCr -443.15Cr -434.04Cr -18TCr